
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$22.38
+$0.02 · +0.09%
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Latest quote
$22.38
+$0.02 · +0.09%
After-hours
$21.96
−$0.42 · -1.88%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Day range
Current $22.38
52-week range
Current $22.38
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
49
Fair Value
Sentiment
68
Bullish
Risk
51
Elevated Risk
Momentum
46
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Day range
Current $22.38
52-week range
Current $22.38
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 239.44M USD | 313.9M USD | 322.42M USD | 284.39M USD | 230.47M USD |
| Cost of goods sold | 57.02M USD | 74.32M USD | 69.76M USD | 61.01M USD | 51.84M USD |
| Gross profit | 182.42M USD | 239.58M USD | 252.65M USD | 223.38M USD | 178.64M USD |
| Research and development | 40.06M USD | 53.97M USD | 44.4M USD | 35.98M USD | 33.86M USD |
| Selling, general, and administrative | 188.31M USD | 198.22M USD | 180.15M USD | 143.6M USD | 111.44M USD |
| Operating expenses | 228.37M USD | 252.19M USD | 224.55M USD | 179.58M USD | 145.3M USD |
| Interest income | 4.59M USD | 5.91M USD | 6.99M USD | 2.45M USD | — |
| Interest expense | — | — | — | — | 38K USD |
| Depreciation and amortization | 8.32M USD | 6.89M USD | 5.12M USD | 4.51M USD | 3.64M USD |
| Operating income | −45.95M USD | −12.61M USD | 28.1M USD | 43.8M USD | 33.34M USD |
| Net income | −80.45M USD | −20.21M USD | 21.35M USD | 39.67M USD | 27.51M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$30.89
38.03% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 18, 1992 | 1:2 | — | — |
Stock split | Nov 1, 1990 | 1:2 | — | — |
Stock split | Nov 9, 1984 | 2:1 | — | — |
Stock split | Jul 3, 1984 | 2:1 | — | — |
Effective May 18, 1992
1:2
Effective Nov 1, 1990
1:2
Effective Nov 9, 1984
2:1
Effective Jul 3, 1984
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR40.21M0.04%104.29B USD0.06%$137.31+0.17%
Vanguard Morningstar Total Stock Market ETFVTI21.45M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM17.93M0.02%78.56B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap ETFVB15.51M0.01%185.3B USD0.03%$287.63+0.23%
Vanguard Extended Market ETFVXF13.03M0.01%95.4B USD0.05%$233.13-0.15%
Vanguard Morningstar Small-Cap Growth ETFVBK8.86M0.02%44.7B USD0.05%$340.59-0.48%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM6.28M0.04%16.01B USD0.03%$53.36+0.15%
Dimensional - US Small Cap ETFDFAS5.95M0.02%33.66B USD0.31%$78.10+0.23%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Vanguard Extended Market ETFVXF
Vanguard Morningstar Small-Cap Growth ETFVBK
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Dimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.